## IONS: Ionis Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.3% below STRENGTH zone (3.0-6.0%); PEG 25.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($75.80)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Hudson Bay Capital Management LP**
- Source: MarketBeat | 20251214T130931 | Neutral | Relevance: 100%
- Hudson Bay Capital Management LP reduced its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 28.6% in Q2, selling 299,900 shares and retaining 750,000 shares valued at approximately $29.6 million. Despite significant insider selling over the past 90 days, Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $84.85 for the stock. Ionis Pharmaceuticals recently exceeded revenue and EPS estimates and is currently trading near its 12-month high.

**2. Marex Group plc Buys New Shares in Ionis Pharmaceuticals, Inc. $IONS**
- Source: MarketBeat | 20251214T120931 | Somewhat-Bullish | Relevance: 100%
- Marex Group plc has acquired a new stake of 83,361 shares in Ionis Pharmaceuticals, Inc. valued at approximately $3.29 million during the second quarter. Institutional investors now own 93.86% of the company, while company insiders have been net sellers, offloading over 500,000 shares. Despite insider selling, Ionis Pharmaceuticals reported a revenue and EPS beat for the quarter, and analysts generally hold a "Moderate Buy" rating with an $84.85 price target.

**3. Adage Capital Partners GP L.L.C. Raises Position in Ionis Pharmaceuticals, Inc. $IONS**
- Source: MarketBeat | 20251213T080843 | Somewhat-Bullish | Relevance: 100%
- Adage Capital Partners GP L.L.C. significantly increased its stake in Ionis Pharmaceuticals, Inc. ($IONS) by 253.3% in the second quarter, now owning 3.8 million shares valued at over $150 million. Other institutional investors also adjusted their positions in Ionis, which saw its stock open at $80.82 and analysts assign an average rating of "Moderate Buy." Insider activity showed executives selling shares, while the company reported better-than-expected quarterly earnings but a negative EPS for the current fiscal year.

**4. B of A Securities Maintains Ionis Pharmaceuticals (IONS) Buy Recommendation**
- Source: Nasdaq | 20251210T100944 | Bullish | Relevance: 100%
- B of A Securities has reiterated its Buy recommendation for Ionis Pharmaceuticals (IONS). Analysts project a 5.02% upside with an average one-year price target of $85.60/share, and institutional funds show a bullish outlook with a put/call ratio of 0.57. Several major funds hold significant positions, with some increasing their portfolio allocations in IONS.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | B of A Securiti | $97 | $86 | +13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($8.92M) |
| Sells | 20 ($5.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- FMR, LLC: 14.6% (+0.2%)
- Vanguard Group Inc: 10.2% (-1.4%)
- T. Rowe Price Invest: 8.1% (-18.0%)
- Capital World Invest: 7.8% (+1.5%)
- Blackrock Inc.: 6.5% (-4.1%)

### Key Risks

1. Insider selling cluster: $5.9M in recent transactions.
2. Valuation stretched: PEG 25.7x requires aggressive growth execution.
3. Elevated short interest (12.7%): bears positioning against stock.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 25.70 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.8x). Analyst sentiment positive (1 raises, avg +13%). Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $13.1B |
| Beta | 0.30 |
| 52W Range | $23.95 - $83.61 |
| Short Interest | 12.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 25.70 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -0.9% to 1.3% (+2.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.7pp (needs >3.0% for momentum thesis). MRS_5 at 2.7% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.29% (CS: 43) | Neutral |
| RSI_14 | 61.2 | Neutral |
| MACD Histogram | -0.38 | Bearish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 1.083x | Above |
| vs SMA200 | 1.659x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $80.82
- **Stop Loss:** $75.80 (6.2% risk)
- **Target:** $85.84 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 199
- **Position Value:** $16,083.18
- **Portfolio %:** 16.08%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.05 | $-0.61 | +41.8% |
| 2025Q2 | $0.16 | $0.85 | +415.1% |
| 2025Q1 | $-1.03 | $-0.92 | +10.4% |
| 2024Q4 | $-0.84 | $-0.43 | +49.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*